

Disclosures

Personal Commercial (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Goodpath	Ownership Interest/Partnership/Principal	Modest (< \$5,000)	<i>Other</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (7)

Trial Name	Trial Sponsor	Trial Funding Source
Abbott Next Generation Drug Eluting Stent 48mm Study (SPIRIT 48)	Abbott Laboratories	
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function (PROTECT IV)	Abiomed	
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial (DTU-STEMI)	Abiomed	
Evaluation of Treatment Strategies for Severe CaLclfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial	Cardiovascular Systems Inc.	
Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE-STEMI for Seniors)	Duke University Medical Center	
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Evinacumab In Patients With Homozygous Familial Hypercholesterolemia	Regeneron	
Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)	Shanghai MicroPort Medical (Group) Co., Ltd.	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (3)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2022	contrast allergy	Plaintiff	death from anaphylactic shock due to contrast allergy	Significant (>= \$5,000)
2021	negligence	Plaintiff	death from nursing negligence in monitoring and reporting vital signs	Significant (>= \$5,000)
2020	amiodarone toxicity	Plaintiff † none	a case of death from amiodarone toxicity due to pharmacy refill error	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 1/8/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 1/8/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 1/8/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 1/8/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.